Bayer Must Study Side Effects of Permanent Birth Control
- Adverse events include pelvic pain and uterus perforation
- FDA recommends a boxed warning for sterilization devices
This article is for subscribers only.
Bayer AG must do a study of its permanent birth control device Essure while it’s on the market to help better understand the potential risks to users, the Food and Drug Administration said Monday.
“While the FDA believes Essure remains an appropriate option for the majority of women seeking a permanent form of birth control, some women may be at risk for serious complications,” the FDA said in a statement.